Abstracts tagged "gout"

Abstract Number: 2228 • 2018 ACR/ARHP Annual Meeting
A Validated Script Concordance Test Demonstrates Interdisciplinary Differences in Clinical Decision-Making When Using Allopurinol to Treat Gout in Chronic Kidney Disease
Nicholas Lebedoff¹, Sarah Gilligan¹, Andrea Barker², Curry L. Koening³, Kelly Starman⁴, Christina Gallop⁵, Bernadette C. Siaton⁶, Kalani L. Raphael^4,7 and Michael J. Battistone⁸, ¹Internal Medicine, University of Utah, Salt Lake City, UT, ²Salt Lake City VAMC and University of Utah, North Salt Lake, UT, ³Rheumatology, Division of Rheumatology, University of Utah, Salt Lake City, UT, ⁴Salt Lake City VA Medical Center, Salt Lake City, UT, ⁵Primary Care, Salt Lake City VA Medical Center, Salt Lake City, UT, ⁶University of Maryland, Baltimore, MD, ⁷Nephrology, University of Utah, Salt Lake City, UT, ⁸Division of Rheumatology, Salt Lake City VA and University of Utah, Salt Lake City, UT
Background/Purpose: The safety of allopurinol in the setting of chronic kidney disease (CKD) has been a controversial issue for many years. The perceived increased risk…
Abstract Number: 870 • 2018 ACR/ARHP Annual Meeting
Patient-Reported Burden of Gout in 2017 from the United States
Puja P. Khanna¹, Douglas C.A. Taylor², An-Chen Fu² and Robert Morlock³, ¹University of Michigan, Ann Arbor, MI, ²Ironwood Pharmaceuticals, Inc., Cambridge, MA, ³YourCareChoice, Ann Arbor, MI
Background/Purpose: Gout is reported to impact 3.9% of the US adult population (Zhu. Arthritis Rheum 2011;63:3136-41). Treatment encompasses controlling acute attacks (flares) and, dependent on…
Abstract Number: 1272 • 2018 ACR/ARHP Annual Meeting
Quality of Gout Management in a Rheumatology Clinic Using a Provider-Pharmacist Team-Based Approach
Jessica Michaud¹ and Jenna Beatty², ¹Pharmacy, Froedtert & the Medical College of Wisconsin, Milwaukee, WI, ²University of Kansas, kansas city, MO
Background/Purpose: Gout is the most common form of inflammatory arthritis.1 The cornerstone of treatment for gout is urate-lowering therapy (ULT), which in the U.S. includes…
Abstract Number: 2237 • 2018 ACR/ARHP Annual Meeting
Prevalence of Urate-Lowering Therapy Use and Target Urate Level Achievement Among Gout Patients in the United States (National Health And Nutrition Examination Survey [NHANES] 2007-2014)
Michael Chen-Xu¹, Chio Yokose², Michael Pillinger³ and Hyon K. Choi², ¹General Medicine, Wairarapa District Health Board, Masterton, New Zealand, ²Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, ³Medicine/Rheumatology, NYU School of Medicine, New York, NY
Background/Purpose: To determine the latest national prevalence of urate-lowering therapy (ULT) use and achievement of a therapeutic target serum urate level (SUL) in gout patients,…
Abstract Number: 357 • 2017 ACR/ARHP Annual Meeting
Determinants of Patient and Physician Disagreement on Presence of a Gout Flare
Aprajita Jagpal¹, Nicola Dalbeth², William J. Taylor³, Kenneth Saag¹, Jasvinder A. Singh⁴, Amy S. Mudano⁵, Elizabeth J. Rahn⁶ and Angelo L. Gaffo⁶, ¹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²University of Auckland, Auckland, New Zealand, ³University of Otago, Wellington, New Zealand, ⁴Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Department of Medicine, Division of Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Flare is a central feature of gout and patient self-report of flare was found to be an important element in a gout flare definition…
Abstract Number: 1139 • 2017 ACR/ARHP Annual Meeting
Management of Gout – a Survey for Healthcare Providers in South Australia
Nieves Leonardo¹ and Julian McNeil², ¹Rheumatology, The Queen Elizabeth Hospital, Woodville South, Australia, ²Rheumatology, Northern Adelaide Local Health Network, Modbury, Australia
Background/Purpose: Gout is a treatable arthritis and while the rate of gout in Australia has been steadily rising, drugs used to treat acute gouty arthritis…
Abstract Number: 2077 • 2017 ACR/ARHP Annual Meeting
Statin Use and Mortality in Gout: A General Population-Based Cohort Study
Sarah Keller¹, Sharan K. Rai², Na Lu¹, Amar Oza³, Yuqing Zhang⁴ and Hyon K. Choi², ¹Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Allergy, Immunology, and Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴School Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Although the cardinal feature of gout is inflammatory arthritis, it is also a metabolic condition closely associated with an elevated uric acid burden and…
Abstract Number: 1090 • 2017 ACR/ARHP Annual Meeting
A Multidisciplinary Performance Improvement Approach to Achieving Goal Serum Uric Acid Levels in Patients with Gout
Luke Monteagudo¹, Jefferson Roberts², Donna Kido³, Collette Chin³ and Susan Fujii³, ¹Internal Medicine, Tripler Army Medical Center, Honolulu, HI, ²Rheumatology, Tripler Army Medical Center, Honolulu, HI, ³Pharmacy, Tripler Army Medical Center, Honolulu, HI
Background/Purpose: In patients with gout, hyperuricemia leads to inflammation induced by mono-sodium urate crystal deposition. This causes irreversible physical and radiographically evident destruction of the…
Abstract Number: 1864 • 2017 ACR/ARHP Annual Meeting
Longitudinal Changes in Serum Uric Acid Levels and Associated Risk of Cardiometabolic Events and Renal Insufficiency in Gout Patients
Rishi J. Desai¹, Jessica Franklin², Julia Spoendlin², Goodarz Danaei³, Daniel H. Solomon⁴ and Seoyoung C. Kim⁵, ¹PharmacoEpidemiology & PharmacoEconomics, Brigham & Women's Hospital, Boston, MA, ²Brigham & Women's Hospital, Boston, MA, ³Harvard School of Public Health, Boston, MA, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Gout patients have an increased risk of type 2 diabetes mellitus (T2DM), cardiovascular disease (CVD), and chronic kidney disease (CKD); however, it is not…
Abstract Number: 2078 • 2017 ACR/ARHP Annual Meeting
Hypersensitivity Reactions with Allopurinol and Febuxostat in Adults 65 Years or Older: A Study Using the Medicare Claims Data
Jasvinder A. Singh¹ and John Cleveland², ¹Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Rheumatology, University of Alabama at Birmingham (UAB), Birmingham, AL
Background/Purpose: Clinicians using allopurinol are always concerned about the risk of rare hypersensitivity reaction. Allopurinol and febuxostat are the two most common urate-lowering agents used…
Abstract Number: 1107 • 2017 ACR/ARHP Annual Meeting
An Illness By Any Other Name: The Effect of Changing the Disease Label of Gout on the Perceptions of the Illness and Its Management
Keith Petrie¹, Kate MacKrill¹, Christina Derksen² and Nicola Dalbeth¹, ¹University of Auckland, Auckland, New Zealand, ²University of Marburg, Marburg, Germany
Background/Purpose: Gout is a chronic disease caused by deposition of monosodium urate crystals. Although diet is a risk factor, many other factors also contribute to…
Abstract Number: 2052 • 2017 ACR/ARHP Annual Meeting
Apply Musculoskeletal Ultrasonography to Predict Chronic Gouty Arthritis in Patients with Chronic Kidney Diseases
Zheng-Hao Huang¹, Chi-Ching Chang², En Chao³, Hui-Hsun Chiang⁴, Shu-Yi Lin⁵, Kun-Lin Wu⁶, Hsiang-Cheng Chen⁵, Shi-Jye Chu⁵, San-Yuan Kao⁵, Tsung-Yun Hou⁵, Feng-Cheng Liu⁵, Chen-Hung Chen⁷, Deh-Ming Chang⁸ and Chun-Chi Lu⁹, ¹Division of Rheumatology, Immunology and Allergy, Department of Internal Medicine, Kaohsiung Armed Forces General Hospital; Tri-service general hospital, National Defense Medical Center, Taipei, Taiwan, ²Taipei Medical University Hospital, Taipei, Taiwan, ³Tri-Service General Hospital Songshan Branch, Taipei, Taiwan, ⁴School of Nursing, National Defense Medical Center, Taipei, Taiwan, ⁵Tri-Service General Hospital, Taipei, Taiwan, ⁶Armed Forces Taoyuan General Hospital, Taipei, Taiwan, ⁷Taipei Tzu Chi hospital, Taipei, Taiwan, ⁸Taipei Veterans General Hospital, Taipei, Taiwan, ⁹University of Washington; Tri-Service General Hopsital, National Defense Medical Center, Seattle, WA
Background/Purpose: Gouty arthritis, caused by the deposition of monosodium urate (MSU) monohydrate crystals at joints, is comprised of multiple inflammatory processes in synovium, tendons, cartilages…
Abstract Number: 2084 • 2017 ACR/ARHP Annual Meeting
Patients with Early Onset Gout Develop Earlier Severe Joint Involvement and Metabolic Comorbid Conditions
Tristan Pascart¹, Laurène Norberciak², Hang-Korng Ea³, Sabine Lanz⁴, Charles Lambert⁵, Pascal Guggenbuhl⁶ and Frederic Liote⁷, ¹Rheumatology, Lille Catholic University, Lille, France, ²Lille Catholic University, Lille, France, ³INSERM UMR1132, Paris Diderot University, Paris, France, ⁴Laboratoire Mayoli Spindler, Chatou, France, ⁵Laboratoire Ipsen Pharma, Boulogne, France, ⁶Rennes University, Rennes, France, ⁷University Paris Diderot, Paris, France
Patients with Early Onset Gout develop Earlier Severe Joint Involvement and Metabolic Comorbid Conditions Background/Purpose: Early onset gout might encompass more severe cases along with genetic defects,…
Abstract Number: 1108 • 2017 ACR/ARHP Annual Meeting
Effect of Body Mass Index on Serum Urate and Renal Uric Acid Handling Responses to an Oral Inosine Load
Nicola Dalbeth¹, Jordyn de Kwant¹, Gregory Gamble², Amanda Phipps-Green³, Anne Horne², Lisa K. Stamp⁴ and Tony R. Merriman⁵, ¹University of Auckland, Auckland, New Zealand, ²Department of Medicine, University of Auckland, Auckland, New Zealand, ³University of Otago, Dunedin, New Zealand, ⁴University of Otago, Christchurch, New Zealand, ⁵Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand
Background/Purpose: Increased body mass index (BMI) is an important risk factor for hyperuricemia and gout. It is unknown whether overweight and obesity influences serum urate…
Abstract Number: 2056 • 2017 ACR/ARHP Annual Meeting
Performance and Validity of Musculoskeletal Ultrasound in the Assessment of Synovial Inflammation in Experimental Acute Gout
Raquel Largo¹, Juan Pablo Medina², Sandra Perez-Baos², Victor Najera-Aleson², Aranzazu Mediero², Gabriel Herrero-Beaumont¹ and Esperanza Naredo³, ¹Bone and Joint Research Unit, IIS-Fundacion Jimenez Diaz UAM, Madrid, Spain, ²Joint and Bone Research Unit, IIS-Fundacion Jimenez Diaz UAM, Madrid, Spain, ³Rheumatology, Joint and Bone Research Unit, IIS-FJD, Hospital Universitario Fundación Jiménez Díaz., Madrid, Spain
Background/Purpose: Musculoskeletal ultrasound (MS-US) has not been validated as a reliable technique to evaluate joint inflammation in an acute gout rabbit model. Rabbit has been…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].